Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Do older adults with shoulder disorders who meet the minimal clinically important difference also present low disability at discharge? An observational study.

Garcia AN, Thigpen CA, Lake AD, Martinez C, Myers H, Cook C.

Braz J Phys Ther. 2019 Feb 27. pii: S1413-3555(18)30832-3. doi: 10.1016/j.bjpt.2019.02.003. [Epub ahead of print]

PMID:
30885628
2.

Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.

Lake AD, Hardwick RN, Leamon CP, Low PS, Cherrington NJ.

Toxicol Appl Pharmacol. 2019 Apr 1;368:49-54. doi: 10.1016/j.taap.2019.02.009. Epub 2019 Feb 19.

PMID:
30794826
3.
4.

Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model.

Han J, Dzierlenga AL, Lu Z, Billheimer DD, Torabzadeh E, Lake AD, Li H, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lehman-McKeeman LD, Cherrington NJ.

Obesity (Silver Spring). 2017 Jun;25(6):1069-1076. doi: 10.1002/oby.21855. Epub 2017 Apr 28.

5.

Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ.

Liver Int. 2017 Jul;37(7):1074-1081. doi: 10.1111/liv.13362. Epub 2017 Feb 7.

6.

Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis.

Lake AD, Chaput AL, Novak P, Cherrington NJ, Smith CL.

Biochem Pharmacol. 2016 Dec 15;122:62-71. doi: 10.1016/j.bcp.2016.11.006. Epub 2016 Nov 9.

7.

Dose and Effect Thresholds for Early Key Events in a PPARα-Mediated Mode of Action.

Lake AD, Wood CE, Bhat VS, Chorley BN, Carswell GK, Sey YM, Kenyon EM, Padnos B, Moore TM, Tennant AH, Schmid JE, George BJ, Ross DG, Hughes MF, Corton JC, Simmons JE, McQueen CA, Hester SD.

Toxicol Sci. 2016 Feb;149(2):312-25. doi: 10.1093/toxsci/kfv236. Epub 2015 Oct 31.

PMID:
26519955
8.

Latent carcinogenicity of early-life exposure to dichloroacetic acid in mice.

Wood CE, Hester SD, Chorley BN, Carswell G, George MH, Ward W, Vallanat B, Ren H, Fisher A, Lake AD, Okerberg CV, Gaillard ET, Moore TM, Deangelo AB.

Carcinogenesis. 2015 Jul;36(7):782-91. doi: 10.1093/carcin/bgv057. Epub 2015 Apr 25.

PMID:
25913432
9.

Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ.

Amino Acids. 2015 Mar;47(3):603-15. doi: 10.1007/s00726-014-1894-9. Epub 2014 Dec 23.

10.

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ.

Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.

11.

Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ.

Toxicol Sci. 2014 Nov;142(1):45-55. doi: 10.1093/toxsci/kfu156. Epub 2014 Jul 31.

12.

Synergistic interaction between genetics and disease on pravastatin disposition.

Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ.

J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.

13.

Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ.

J Pharmacol Exp Ther. 2014 Mar;348(3):452-8. doi: 10.1124/jpet.113.211284. Epub 2014 Jan 8.

14.

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ.

Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.

15.

Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis.

Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ.

J Appl Toxicol. 2014 Jun;34(6):726-32. doi: 10.1002/jat.2960. Epub 2013 Nov 12.

16.

The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Hardwick RN, Flores-Keown B, Zhao F, Klimecki WT, Cherrington NJ.

Toxicol Sci. 2014 Jan;137(1):26-35. doi: 10.1093/toxsci/kft230. Epub 2013 Oct 4.

17.

Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ.

Dig Dis Sci. 2014 Feb;59(2):365-74. doi: 10.1007/s10620-013-2873-9. Epub 2013 Sep 19.

18.

Impact of objectively assessing surgeons' teaching on effective perioperative instructional behaviors.

Anderson CI, Gupta RN, Larson JR, Abubars OI, Kwiecien AJ, Lake AD, Hozain AE, Tanious A, O'Brien T, Basson MD.

JAMA Surg. 2013 Oct;148(10):915-22. doi: 10.1001/jamasurg.2013.2144.

PMID:
23945792
19.
20.

Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ.

Toxicol Appl Pharmacol. 2013 Apr 15;268(2):132-40. doi: 10.1016/j.taap.2013.01.022. Epub 2013 Feb 4.

21.

Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington NJ.

Drug Metab Dispos. 2013 Mar;41(3):554-61. doi: 10.1124/dmd.112.048439. Epub 2012 Dec 7.

22.

Altered arsenic disposition in experimental nonalcoholic fatty liver disease.

Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ.

Drug Metab Dispos. 2012 Sep;40(9):1817-24. doi: 10.1124/dmd.112.046177. Epub 2012 Jun 14.

23.

Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.

Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ.

Drug Metab Dispos. 2011 Oct;39(10):1954-60. doi: 10.1124/dmd.111.040592. Epub 2011 Jul 7.

24.

Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ.

Drug Metab Dispos. 2010 Dec;38(12):2293-301. doi: 10.1124/dmd.110.035006. Epub 2010 Aug 30.

25.

Development of high-yield autofluorescent protein microarrays using hybrid cell-free expression with combined Escherichia coli S30 and wheat germ extracts.

Zárate X, Henderson DC, Phillips KC, Lake AD, Galbraith DW.

Proteome Sci. 2010 Jun 15;8:32. doi: 10.1186/1477-5956-8-32.

Supplemental Content

Support Center